Why the study?
Does multivessel PCI reduce long-term death or increase contrast-induced nephropathy in patients with UA/NSTEMI and non-diabetic CKD compared to culprit-vessel only PCI?
Does multivessel PCI reduce long-term death or increase contrast-induced nephropathy in patients with UA/NSTEMI and non-diabetic CKD compared to culprit-vessel only PCI?
Answers are grounded in this paper and cite their sources.
In patients with UA/NSTEMI and non-diabetic CKD (eGFR > 30), multivessel PCI is associated with reduced long-term mortality without increasing contrast-induced nephropathy compared to culprit-vessel only PCI, with staged procedures potentially being preferable.
Among patients with UA/NSTEMI and non-diabetic CKD and an eGFR > 30 mL/min/1.73 m² , MV-PCI was associated with a reduced risk of long-term death but did not increase the incidence of CIN during the management of MVD compared to CV-PCI. And staged procedures might be a preferable option over single-procedure MV-PCI.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: